Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regeneron PharmaceuticalsLTS:0R2M +2.02%87 Return-on-Tangible-Asset is 7.37% as of Mar. 2026, which is 53% below its 10-year median of 15.59. GuruFocus rates LTS:0R2M with a GF Score™ of 87/100 and a GF Value™ of $902.50 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,415 Biotechnology companies, Regeneron Pharmaceuticals ranks better than 91.87% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Regeneron Pharmaceuticals's annualizedNet Income for the quarter that ended in Mar. 2026 was $2,909 Mil. Regeneron Pharmaceuticals's average total tangible assets for the quarter that ended in Mar. 2026 was $39,442 Mil. Therefore, Regeneron Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 7.37%.
The historical rank and industry rank for Regeneron Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:
LTS:0R2M'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 11.58 Med: 15.59 Max: 37.92
Current: 11.58
During the past 13 years, Regeneron Pharmaceuticals's highest Return-on-Tangible-Asset was 37.92%. The lowest was 11.58%. And the median was 15.59%.
LTS:0R2M's Return-on-Tangible-Asset is ranked better than 91.87% of 1415
companies
in the Biotechnology industry
Industry Median: -35.75
vs LTS:0R2M: 11.58
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Regeneron Pharmaceuticals Return-on-Tangible-Asset Related Terms
Regeneron Pharmaceuticals Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Regeneron Pharmaceuticals's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R2M vs RVMD, ALNY, ONC: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 7.37% mean?
Regeneron Pharmaceuticals (LTS:0R2M) has a Return-on-Tangible-Asset of 7.37% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Regeneron Pharmaceuticals and its competitors. This is 53% below median its historical median of 15.59. Over the past decade, Regeneron Pharmaceuticals' Return-on-Tangible-Asset has ranged from 11.58 to 37.92. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #115 out of 1415 companies in the Biotechnology industry, placing it in the top 8.1%.
Is Regeneron Pharmaceuticals' Return-on-Tangible-Asset too high?
Regeneron Pharmaceuticals' current Return-on-Tangible-Asset of 7.37% is 53% below median its 10-year median of 15.59. Over the past 10 years, this metric has ranged from a low of 11.58 to a high of 37.92. Based on the distribution chart, Regeneron Pharmaceuticals ranks #115 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Return-on-Tangible-Asset compare to RVMD and ALNY?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #115 out of 1415 companies for Return-on-Tangible-Asset. This places Regeneron Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. Historically, Regeneron Pharmaceuticals' own Return-on-Tangible-Asset has ranged from 11.58 to 37.92 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Return-on-Tangible-Asset is 7.37%, which is 53% below median its own 10-year median of 15.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Modestly Undervalued. The stock's GF Value™ is $902.50, compared to a current price of $662.48 — trading 26.6% below its estimated fair value. The current Return-on-Tangible-Asset is 7.37%, which is 53% below median its 10-year median of 15.59. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current Return-on-Tangible-Asset is 7.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of $662.48 is trading 26.6% below its estimated GF Value™ of $902.50.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for LTS:0R2M:
Return-on-Tangible-Asset: 7.37% (53% below median its 10-year median of 15.59)
GF Value™: $902.50 vs. price of $662.48 (26.6% below fair value)
No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score
Get the complete analysis for LTS:0R2M
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2M has been successfully added to your 
